Catalysts · GSK · CIK 1131399 · page 2 of 4

GSK catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on GSK PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
Aug to Nov 2027Quarter disclosedhz/su vaccineGSKTopline readoutHerpes ZosterScheduledClinicalTrials.gov
Aug to Nov 2027Quarter disclosedcamlipixant (BLU-5937)GSKTopline readoutRefractory Chronic CoughScheduledClinicalTrials.gov
August 2027Month disclosedhz/su vaccineGSKPrimary completionHerpes ZosterScheduledClinicalTrials.gov
August 2027Month disclosedcamlipixant (BLU-5937)GSKPrimary completionRefractory Chronic CoughScheduledClinicalTrials.gov
Oct 2027 to Jan 2028Quarter discloseddepemokimab (GSK3511294)GSKTopline readoutHypereosinophilic SyndromeScheduledClinicalTrials.gov
Oct 2027 to Jan 2028Quarter disclosedJemperli (dostarlimab)GSKTopline readoutNeoplasms, RectalScheduledClinicalTrials.gov
Oct 2027 to Jan 2028Quarter disclosedVH4524184GSKTopline readoutHIV InfectionsScheduledClinicalTrials.gov
Oct 2027 to Jan 2028Quarter disclosedgsk3772701 600 mg (GSK3772701)GSKTopline readoutMalaria, FalciparumScheduledClinicalTrials.gov
October 2027Month disclosedgsk3772701 600 mg (GSK3772701)GSKPrimary completionMalaria, FalciparumScheduledClinicalTrials.gov
October 2027Month disclosedJemperli (dostarlimab)GSKPrimary completionNeoplasms, RectalScheduledClinicalTrials.gov
October 2027Month disclosedVH4524184GSKPrimary completionHIV InfectionsScheduledClinicalTrials.gov
October 2027Month discloseddepemokimab (GSK3511294)GSKPrimary completionHypereosinophilic SyndromeScheduledClinicalTrials.gov
Nov 2027 to Feb 2028Quarter disclosedGSK4532990GSKTopline readoutLiver Diseases, AlcoholicScheduledClinicalTrials.gov
Nov 2027 to Feb 2028Quarter disclosedrisvutatug rezetecan (ris-rez)GSKTopline readoutNeoplasms, LungScheduledClinicalTrials.gov
Nov 2027 to Feb 2028Quarter disclosedvelzatinib (IDRX-42)GSKTopline readoutGastrointestinal NeoplasmsScheduledClinicalTrials.gov
November 2027Month disclosedrisvutatug rezetecan (ris-rez)GSKPrimary completionNeoplasms, LungScheduledClinicalTrials.gov
November 2027Month disclosedGSK4532990GSKPrimary completionLiver Diseases, AlcoholicScheduledClinicalTrials.gov
November 2027Month disclosedvelzatinib (IDRX-42)GSKPrimary completionGastrointestinal NeoplasmsScheduledClinicalTrials.gov
early 2028Half-year disclosedDREAMM-10GSKInterim readout—ScheduledSEC Form 8-K
Jan to Apr 2028Quarter discloseddepemokimab (GSK3511294)GSKTopline readoutAsthmaScheduledClinicalTrials.gov
January 2028Month discloseddepemokimab (GSK3511294)GSKPrimary completionAsthmaScheduledClinicalTrials.gov
Feb to May 2028Quarter disclosedmocertatug rezetecanGSKTopline readoutNeoplasms, EndometrialScheduledClinicalTrials.gov
Feb to May 2028Quarter disclosedmmrvnsGSKTopline readoutMeasles; Measles-Mumps-Rubella+Chickenpox VaccineScheduledClinicalTrials.gov
February 2028Month disclosedmmrvnsGSKPrimary completionMeasles; Measles-Mumps-Rubella+Chickenpox VaccineScheduledClinicalTrials.gov
February 2028Month disclosedmocertatug rezetecanGSKPrimary completionNeoplasms, EndometrialScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedefimosfermin alfaGSKTopline readoutNon-alcoholic Fatty Liver DiseaseScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedefimosfermin alfaGSKTopline readoutNon-alcoholic Fatty Liver DiseaseScheduledClinicalTrials.gov
March 2028Month disclosedefimosfermin alfaGSKPrimary completionNon-alcoholic Fatty Liver DiseaseScheduledClinicalTrials.gov
March 2028Month disclosedefimosfermin alfaGSKPrimary completionNon-alcoholic Fatty Liver DiseaseScheduledClinicalTrials.gov
Apr to Jul 2028Quarter disclosedlow dose of ints-tcvGSKTopline readoutSalmonella InfectionsScheduledClinicalTrials.gov
April 2028Month disclosedlow dose of ints-tcvGSKPrimary completionSalmonella InfectionsScheduledClinicalTrials.gov
May to Aug 2028Quarter disclosedvelzatinib - subject to usan approval (IDRX-42)GSKTopline readoutGastrointestinal NeoplasmsScheduledClinicalTrials.gov
May 2028Month disclosedvelzatinib - subject to usan approval (IDRX-42)GSKPrimary completionGastrointestinal NeoplasmsScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedJemperli (dostarlimab)GSKTopline readoutNeoplasms, Head and NeckScheduledSEC 8-K Exhibit 99.1
Jun to Sep 2028Quarter disclosedmmrvns vaccineGSKTopline readoutMeasles; Mumps; RubellaScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedmrna seasonal flu vaccineGSKTopline readoutInfluenza, HumanScheduledClinicalTrials.gov
June 2028Month disclosedmrna seasonal flu vaccineGSKPrimary completionInfluenza, HumanScheduledClinicalTrials.gov
June 2028Month disclosedmmrvns vaccineGSKPrimary completionMeasles; Mumps; RubellaScheduledClinicalTrials.gov
June 2028Month disclosedJemperli (dostarlimab)GSKPrimary completionNeoplasms, Head and NeckScheduledClinicalTrials.gov
Jul to Oct 2028Quarter disclosedefimosfermin (BOS-580)GSKTopline readoutMetabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver DiseaseScheduledClinicalTrials.gov
July 2028Month disclosedefimosfermin (BOS-580)GSKPrimary completionMetabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver DiseaseScheduledClinicalTrials.gov
Aug to Nov 2028Quarter disclosedefimosfermin alfaGSKTopline readoutLiver Diseases, AlcoholicScheduledClinicalTrials.gov
August 2028Month disclosedefimosfermin alfaGSKPrimary completionLiver Diseases, AlcoholicScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedGSK4527226GSKTopline readoutAlzheimer's DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedGSK4527226GSKPrimary completionAlzheimer's DiseaseScheduledClinicalTrials.gov
Oct 2028 to Jan 2029Quarter disclosedaltsonflex1-2-3 dose aGSKTopline readoutDiarrhoeaScheduledClinicalTrials.gov
Oct 2028 to Jan 2029Quarter disclosedlinerixibat (GSK2330672)GSKTopline readoutPruritusScheduledClinicalTrials.gov
October 2028Month disclosedaltsonflex1-2-3 dose aGSKPrimary completionDiarrhoeaScheduledClinicalTrials.gov
October 2028Month disclosedlinerixibat (GSK2330672)GSKPrimary completionPruritusScheduledClinicalTrials.gov
Dec 2028 to Mar 2029Quarter discloseddepemokimab (GSK3511294)GSKTopline readoutPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
Dec 2028 to Mar 2029Quarter discloseddepemokimab (GSK3511294)GSKTopline readoutPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
Dec 2028 to Mar 2029Quarter disclosedOJJAARA (momelotinib)GSKTopline readoutVEXAS SyndromeScheduledClinicalTrials.gov
December 2028Month disclosedOJJAARA (momelotinib)GSKPrimary completionVEXAS SyndromeScheduledClinicalTrials.gov
December 2028Month discloseddepemokimab (GSK3511294)GSKPrimary completionPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
December 2028Month discloseddepemokimab (GSK3511294)GSKPrimary completionPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedHIBSAGO (bepirovirsen)GSKTopline readoutHepatitis BScheduledClinicalTrials.gov
January 2029Month disclosedHIBSAGO (bepirovirsen)GSKPrimary completionHepatitis BScheduledClinicalTrials.gov
Feb to May 2029Quarter disclosedbelantamab mafodotinGSKTopline readoutMultiple MyelomaScheduledClinicalTrials.gov
Feb to May 2029Quarter disclosedGSK5784283GSKTopline readoutAsthmaScheduledClinicalTrials.gov
February 2029Month disclosedGSK5784283GSKPrimary completionAsthmaScheduledClinicalTrials.gov
February 2029Month disclosedbelantamab mafodotinGSKPrimary completionMultiple MyelomaScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedJemperli (dostarlimab)GSKTopline readoutColonic Neoplasms; Neoplasms, ColonScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedcab laGSKTopline readoutHIV InfectionsScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedGSK5784283GSKTopline readoutNasal PolypsScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedGSK5784283GSKTopline readoutNasal PolypsScheduledClinicalTrials.gov
Mar to Jun 2029Quarter disclosedGSK3862995BGSKTopline readoutPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
March 2029Month disclosedGSK5784283GSKPrimary completionNasal PolypsScheduledClinicalTrials.gov
March 2029Month disclosedGSK5784283GSKPrimary completionNasal PolypsScheduledClinicalTrials.gov
March 2029Month disclosedcab laGSKPrimary completionHIV InfectionsScheduledClinicalTrials.gov
March 2029Month disclosedGSK3862995BGSKPrimary completionPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
March 2029Month disclosedJemperli (dostarlimab)GSKPrimary completionColonic Neoplasms; Neoplasms, ColonScheduledClinicalTrials.gov
Apr to Jul 2029Quarter discloseddepemokimab (GSK3511294)GSKTopline readoutPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
April 2029Month discloseddepemokimab (GSK3511294)GSKPrimary completionPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedadjuvanted rzv vaccineGSKTopline readoutCardiovascular DiseaseScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedGSK5784283GSKTopline readoutAsthmaScheduledClinicalTrials.gov
May 2029Month disclosedadjuvanted rzv vaccineGSKPrimary completionCardiovascular DiseaseScheduledClinicalTrials.gov
May 2029Month disclosedGSK5784283GSKPrimary completionAsthmaScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedmocertatug rezetecanGSKTopline readoutNeoplasms, EndometrialScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedGSK5784283GSKTopline readoutPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedGSK5784283GSKTopline readoutPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
July 2029Month disclosedGSK5784283GSKPrimary completionPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
July 2029Month disclosedGSK5784283GSKPrimary completionPulmonary Disease, Chronic ObstructiveScheduledClinicalTrials.gov
July 2029Month disclosedmocertatug rezetecanGSKPrimary completionNeoplasms, EndometrialScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedBenlysta (belimumab)GSKTopline readoutSystemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, SystemicScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedBenlysta (belimumab)GSKTopline readoutLung Diseases, InterstitialScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedcab ulaGSKTopline readoutHIVScheduledClinicalTrials.gov
August 2029Month disclosedcab ulaGSKPrimary completionHIVScheduledClinicalTrials.gov
August 2029Month disclosedBenlysta (belimumab)GSKPrimary completionSystemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, SystemicScheduledClinicalTrials.gov
August 2029Month disclosedBenlysta (belimumab)GSKPrimary completionLung Diseases, InterstitialScheduledClinicalTrials.gov
Sep to Dec 2029Quarter disclosedmocertatug rezetecanGSKTopline readoutOvarian NeoplasmsScheduledClinicalTrials.gov
September 2029Month disclosedmocertatug rezetecanGSKPrimary completionOvarian NeoplasmsScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedrisvutatug rezetecan (ris-rez)GSKTopline readoutNeoplasms, ProstateScheduledClinicalTrials.gov
December 2029Month disclosedrisvutatug rezetecan (ris-rez)GSKPrimary completionNeoplasms, ProstateScheduledClinicalTrials.gov
Mar to Jun 2030Quarter disclosedJemperli (dostarlimab)GSKTopline readoutNeoplasms, EndometrialScheduledClinicalTrials.gov
Mar to Jun 2030Quarter disclosedJemperli (dostarlimab)GSKTopline readoutNeoplasms, RectalScheduledClinicalTrials.gov
March 2030Month disclosedJemperli (dostarlimab)GSKPrimary completionNeoplasms, RectalScheduledClinicalTrials.gov
March 2030Month disclosedJemperli (dostarlimab)GSKPrimary completionNeoplasms, EndometrialScheduledClinicalTrials.gov
May to Aug 2030Quarter disclosedmocertatug rezetecan (mo-rez)GSKTopline readoutOvarian NeoplasmsScheduledClinicalTrials.gov
May 2030Month disclosedmocertatug rezetecan (mo-rez)GSKPrimary completionOvarian NeoplasmsScheduledClinicalTrials.gov
Jul to Oct 2030Quarter disclosedmocertatug rezetecanGSKTopline readoutOvarian NeoplasmsScheduledClinicalTrials.gov
Every catalyst is quoted from GSK’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.